Scans

Tools

Home

Charts

Watchlist

Products

Aster DM Quality Care Ltd

ASTERDM

NSE

₹667.15-1.07%19 Oct 2026 at 3:54 PM

Reports

Hospitals

Aster DM Quality Care Ltd

ASTERDM

NSE

₹667.15

-1.07%

19 Oct 2026 at 3:54 PM

SOICxStockScans Reports

Ask AI

Hospitals

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Deep Dive Report: In-depth business analysis.

Aster DM Healthcare began as a single-doctor clinic in Dubai in 1987 and has since transformed into one of India’s top three private hospital chains by bed capacity, now operating as a pure-play domestic healthcare provider after separating its Gulf business and merging with Blackstone-backed Quality Care India. The recurring approach is to build or acquire hospitals in underserved markets, fill them with high-end clinical talent and technology, and then deepen their profitability by shifting the patient mix toward complex, higher-value procedures - a playbook it has run from its first Indian hospital in Kozhikode to its latest merger creating a pan-India platform.

Business segments

Three engines at different stages - a mature hospital network generating the bulk of cash, a young diagnostics chain approaching breakeven, and a retail pharmacy network being restructured - all stitched together by a digital health backbone.

1. Hospitals and clinics: where the group’s cash and reputation are built

A network of 39 hospitals with over 10,600 beds treats patients across every tier of care, earning revenue on a fee-for-service basis while steadily shifting toward complex, high-value procedures that command better pricing.

Paid per patient, not per bed - revenue comes from in-patient stays and out-patient visits, driven by how many beds are filled (61% occupancy at Aster standalone in FY26), how long patients stay (3.1 days on average), and what the hospital earns per occupied bed (INR 51,800 ARPOB). The combined entity post-merger tracks ARPP IP - average revenue per in-patient - which stood at INR 127,074 in FY26, reflecting the higher-acuity case mix QCIL brings.
Complex procedures lift the ceiling - no single specialty accounts for more than 15% of hospital revenue, but the top six - cardiac sciences, neurology, oncology, liver care, nephrology, and orthopaedics - together contributed 57% in FY25. The company deliberately steers toward these under its CONGO-T framework (Cardiology, Oncology, Neurology, Gastroenterology, Transplants) because they carry higher margins and are harder for smaller rivals to replicate.
Three clusters, three different jobs - the Kerala cluster, anchored by Aster Medcity in Kochi and MIMS in Kozhikode, is the mature profit engine contributing 53% of hospital revenue in FY25. Karnataka and Maharashtra, led by Aster CMI and Aster Whitefield in Bengaluru, is the growth engine at 35% of revenue, while Andhra Pradesh and Telangana is the emerging frontier built around the acquired Ramesh Hospitals group.
Maturity determines margin - hospitals older than seven years delivered a 25.4% EBITDA margin and 36.5% return on capital employed in FY26, while those under three years ran at just 10.5% with zero ROCE, because new hospitals need time to build doctor referrals and patient trust before they can fill beds with higher-paying procedures. This is why the company’s 4,445-bed expansion pipeline - including greenfield projects in Kasargod, Trivandrum, Sarjapur Road Bengaluru, and Hyderabad - is a bet that today’s investment will become tomorrow’s mature cash generator.
An asset-light side door into smaller cities - four hospitals with 554 beds run on an operations-and-maintenance model where Aster manages the facility for a fee rather than owning it, earning both fixed and variable payments at a lower ARPOB of roughly INR 20,000 because these units treat more government-scheme patients. It is a low-risk way to test demand in tier-2 and tier-3 towns before committing capital.

2. Aster Labs: the diagnostics network feeding the hospital funnel

A hub-and-spoke pathology chain of over 300 collection centres and labs runs more than 2,500 types of tests, serving both the company’s own hospitals and external patients while acting as a referral feeder into the hospital system.

Built on the hospital brand - launched in 2019 under the promise “The True Test,” the labs business inherited the trust of a 35-year healthcare name, which matters when patients are choosing where to get blood work or a biopsy read. It now operates one reference lab, 13 satellite labs, nine hospital lab managements, and 248 patient experience centres across six states.
Broke even by plugging into existing infrastructure - the business reached EBITDA breakeven in Q4 FY24 by consolidating hospital lab work under Aster Labs and sharing resources across clusters, so it did not have to build a customer base from scratch. Since inception it has served over 3.24 million patients and performed 12.3 million tests as of March 2023.
A small slice today, a referral engine tomorrow - at 3% of total revenue in FY26, the labs business is modest, but every test result that flags a serious condition creates a direct path into the company’s hospital network for treatment.

3. Aster Pharmacy (India retail): a branded storefront being refocused

A chain of 203 retail pharmacies sells medicines and wellness products under the Aster brand, operated by a separate licensee, while the company has exited a loss-making wholesale unit to stop the drag on growth.

Brand licence, not owned operations - the pharmacies are run by Alfaone Retail Pharmacies Private Limited under a brand licence from Aster, meaning the company earns a fee without carrying the full operating risk of retail. The network spans Karnataka, Kerala, Telangana, and Andhra Pradesh.
Cutting the loss-maker - the company deliberately exited a loss-making wholesale pharmacy unit, which suppressed reported revenue growth but removed a drain on profitability, signalling that this segment is being managed for contribution, not scale at any cost.

Digital health and technology platforms

A shared digital layer - spanning a patient app, an AI-driven reactivation engine, and a 24/7 teleradiology hub - sits across all three businesses to pull patients back into the system and make the network stickier.

The app that speaks the local language - the Aster Health App, launched in November 2024 across 10 hospitals, had over 100,000 downloads and over 20,000 active monthly users by FY25, with a Malayalam version making it Kerala’s first regional-language healthcare super app. It handles appointment booking, lab reports, and radiology reports in one place.
Winning back dormant patients with algorithms - the AsterCare programme analyses health records to identify patients who have stopped coming and re-engages them, achieving an 8% reactivation rate in pilots and recovering over 6,500 patients, which is essentially free revenue from an existing database.
Reading scans while India sleeps - Aster Medical Imaging runs a centralized teleradiology hub that interprets MRI, CT, and X-ray scans remotely for both Aster hospitals and external clients, using time-zone differences to offer overnight reporting for international customers and “pre-read” services. It turns an internal capability into a third-party revenue stream.

Group structure and partners

The listed entity, Aster DM Quality Care Limited, is jointly controlled by the founding Moopen family and Blackstone following a merger that created a top-three pan-India hospital platform, with the legacy Gulf business now entirely separated.

A clean split from the Gulf - on April 3, 2024, a consortium led by sovereign-backed Fajr Capital acquired 65% of the GCC business, while the Moopen family kept 35% and operational rights, leaving the listed India entity as a pure domestic play with the family holding 41.88%. The two sides are bound by a non-compete agreement preventing operations in each other’s core regions.
The Blackstone merger created the scale - effective July 1, 2026, Aster merged with Quality Care India Limited, a Blackstone-backed hospital group, in a share-swap deal that gave Blackstone 30.7% of the combined entity and Aster promoters 24.0%, with equal board representation and joint control. The merged company operates 39 hospitals across 28 cities under four brands - Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare - and has a presence in Bangladesh as well.
Subsidiaries do the heavy lifting - Malabar Institute of Medical Sciences (MIMS), the Kerala hospital operator, is a material subsidiary that Aster is consolidating to 100% ownership. New greenfield projects in Bengaluru - a 430-bed hospital on Sarjapur Road and a super-specialty facility in Yeshwantpur - are housed in separate wholly owned subsidiaries, with external investors brought in via compulsory convertible preference shares while Aster keeps at least 75%.
A captive solar plant to lock in power costs - in April 2026, Aster and MIMS acquired a 26% stake in a solar power developer that will build an 18 MWp plant in Kerala, with the hospitals buying 100% of the output, meeting statutory captive-user rules under the Electricity Act while insulating against grid-price volatility.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹58,245Cr

Close Price

₹668.20

Industry

Hospitals

Price To Earnings

108.12

Price To Sales

11.95

Revenue

₹4,876Cr

Rev Gr TTM

Revenue Growth TTM

15.70%

PAT Gr TTM

PAT Growth TTM

3.89%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	929	955	974	1,002	1,086	1,050	1,000	1,078	1,197	1,186	1,182	1,311
Growth YoY Revenue Growth YoY%	-67.0	-70.1	20.6	19.1	16.9	10.0	2.8	7.6	10.2	12.9	18.2	21.6
Expenses ExpensesCr	784	803	814	838	867	861	808	871	947	975	950	1,046
Operating Profit Operating ProfitCr	145	152	159	164	220	189	192	207	250	211	233	264
OPM OPM%	15.6	15.9	16.4	16.3	20.2	18.0	19.2	19.2	20.9	17.8	19.7	20.2
Other Income Other IncomeCr	1	7	1	46	33	6	-5	23	14	-9	28	-86
Interest Expense Interest ExpenseCr	30	25	30	29	31	31	32	31	31	31	30	31
Depreciation DepreciationCr	54	57	58	60	62	62	64	63	66	68	67	69
PBT PBTCr	61	77	72	120	159	102	91	136	167	103	163	78
Tax TaxCr	8	11	31	39	53	37	5	43	46	44	10	49
PAT PATCr	-15	209	-2	5,152	106	64	86	94	121	59	154	29
Growth YoY PAT Growth YoY%	-128.3	31.6	-101.2	25,855.7	789.4	-69.2	4,060.2	-98.2	14.7	-8.9	79.5	-68.7
NPM NPM%	-1.6	21.9	-0.2	514.3	9.7	6.1	8.6	8.7	10.1	5.0	13.0	2.2
EPS EPS₹	-0.6	3.6	-0.5	103.3	1.9	1.1	1.6	1.7	2.1	1.0	2.7	0.3

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	929	955	974	1,002	1,086	1,050	1,000	1,078	1,197	1,186	1,182	1,311
Growth YoY Revenue Growth YoY%	-67.0	-70.1	20.6	19.1	16.9	10.0	2.8	7.6	10.2	12.9	18.2	21.6
Expenses ExpensesCr	784	803	814	838	867	861	808	871	947	975	950	1,046
Operating Profit Operating ProfitCr	145	152	159	164	220	189	192	207	250	211	233	264
OPM OPM%	15.6	15.9	16.4	16.3	20.2	18.0	19.2	19.2	20.9	17.8	19.7	20.2
Other Income Other IncomeCr	1	7	1	46	33	6	-5	23	14	-9	28	-86
Interest Expense Interest ExpenseCr	30	25	30	29	31	31	32	31	31	31	30	31
Depreciation DepreciationCr	54	57	58	60	62	62	64	63	66	68	67	69
PBT PBTCr	61	77	72	120	159	102	91	136	167	103	163	78
Tax TaxCr	8	11	31	39	53	37	5	43	46	44	10	49
PAT PATCr	-15	209	-2	5,152	106	64	86	94	121	59	154	29
Growth YoY PAT Growth YoY%	-128.3	31.6	-101.2	25,855.7	789.4	-69.2	4,060.2	-98.2	14.7	-8.9	79.5	-68.7
NPM NPM%	-1.6	21.9	-0.2	514.3	9.7	6.1	8.6	8.7	10.1	5.0	13.0	2.2
EPS EPS₹	-0.6	3.6	-0.5	103.3	1.9	1.1	1.6	1.7	2.1	1.0	2.7	0.3

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	5,250	5,931	6,721	7,963	8,652	8,608	10,253	2,994	3,699	4,138	4,643	4,876
Growth Revenue Growth%	35.5	13.0	13.3	18.5	8.7	-0.5	19.1	-70.8	23.5	11.9	12.2	15.7
Expenses ExpensesCr	4,804	5,599	6,108	7,100	7,394	7,546	8,770	2,545	3,121	3,374	3,742	3,918
Operating Profit Operating ProfitCr	446	332	613	863	1,258	1,063	1,483	449	578	765	901	958
OPM OPM%	8.5	5.6	9.1	10.8	14.5	12.3	14.5	15.0	15.6	18.5	19.4	19.6
Other Income Other IncomeCr	24	452	177	33	18	53	51	26	14	79	56	-53
Interest Expense Interest ExpenseCr	189	354	185	179	360	294	257	87	110	124	123	123
Depreciation DepreciationCr	243	322	298	306	586	618	641	192	220	249	264	270
PBT PBTCr	38	108	308	410	330	205	637	195	261	471	570	511
Tax TaxCr	29	11	26	43	15	27	36	36	57	134	143	149
PAT PATCr	8	98	282	367	315	178	601	160	205	337	427	363
Growth PAT Growth%	-97.0	1,088.0	188.8	30.4	-14.3	-43.5	238.0	-73.5	28.3	64.5	26.9	3.9
NPM NPM%	0.2	1.6	4.2	4.6	3.6	2.1	5.9	5.3	5.5	8.1	9.2	7.4
EPS EPS₹		2.2	5.8	6.6	5.5	3.0	10.6	8.5	2.6	108.0	7.5	6.2

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	5,250	5,931	6,721	7,963	8,652	8,608	10,253	2,994	3,699	4,138	4,643	4,876
Growth Revenue Growth%	35.5	13.0	13.3	18.5	8.7	-0.5	19.1	-70.8	23.5	11.9	12.2	15.7
Expenses ExpensesCr	4,804	5,599	6,108	7,100	7,394	7,546	8,770	2,545	3,121	3,374	3,742	3,918
Operating Profit Operating ProfitCr	446	332	613	863	1,258	1,063	1,483	449	578	765	901	958
OPM OPM%	8.5	5.6	9.1	10.8	14.5	12.3	14.5	15.0	15.6	18.5	19.4	19.6
Other Income Other IncomeCr	24	452	177	33	18	53	51	26	14	79	56	-53
Interest Expense Interest ExpenseCr	189	354	185	179	360	294	257	87	110	124	123	123
Depreciation DepreciationCr	243	322	298	306	586	618	641	192	220	249	264	270
PBT PBTCr	38	108	308	410	330	205	637	195	261	471	570	511
Tax TaxCr	29	11	26	43	15	27	36	36	57	134	143	149
PAT PATCr	8	98	282	367	315	178	601	160	205	337	427	363
Growth PAT Growth%	-97.0	1,088.0	188.8	30.4	-14.3	-43.5	238.0	-73.5	28.3	64.5	26.9	3.9
NPM NPM%	0.2	1.6	4.2	4.6	3.6	2.1	5.9	5.3	5.5	8.1	9.2	7.4
EPS EPS₹		2.2	5.8	6.6	5.5	3.0	10.6	8.5	2.6	108.0	7.5	6.2

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	403	505	505	497	497	500	500	500	500	518
Reserves ReservesCr	1,034	1,952	2,334	2,401	2,501	3,080	3,574	3,686	2,554	3,683
Current Liabilities Current LiabilitiesCr	2,201	2,224	2,668	3,722	3,196	3,559	4,655	11,288	879	979
Non Current Liabilities Non Current LiabilitiesCr	2,355	2,071	2,589	4,997	4,614	4,505	5,365	1,673	2,076	2,299
Total Liabilities Total LiabilitiesCr	6,807	7,484	8,936	12,438	11,643	12,546	14,881	17,991	6,606	8,112
Current Assets Current AssetsCr	2,472	2,869	3,617	4,096	3,629	4,096	4,922	14,165	1,901	1,948
Non Current Assets Non Current AssetsCr	4,335	4,615	5,320	8,342	8,014	8,450	9,960	3,826	4,705	6,164
Total Assets Total AssetsCr	6,807	7,484	8,936	12,438	11,643	12,546	14,881	17,991	6,606	8,112

Financial Year	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	403	505	505	497	497	500	500	500	500	518
Reserves ReservesCr	1,034	1,952	2,334	2,401	2,501	3,080	3,574	3,686	2,554	3,683
Current Liabilities Current LiabilitiesCr	2,201	2,224	2,668	3,722	3,196	3,559	4,655	11,288	879	979
Non Current Liabilities Non Current LiabilitiesCr	2,355	2,071	2,589	4,997	4,614	4,505	5,365	1,673	2,076	2,299
Total Liabilities Total LiabilitiesCr	6,807	7,484	8,936	12,438	11,643	12,546	14,881	17,991	6,606	8,112
Current Assets Current AssetsCr	2,472	2,869	3,617	4,096	3,629	4,096	4,922	14,165	1,901	1,948
Non Current Assets Non Current AssetsCr	4,335	4,615	5,320	8,342	8,014	8,450	9,960	3,826	4,705	6,164
Total Assets Total AssetsCr	6,807	7,484	8,936	12,438	11,643	12,546	14,881	17,991	6,606	8,112

Consolidated

Standalone

Financial Year	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	361	537	601	1,223	1,569	1,314	1,834	158	425	656
Investing Cash Flow Investing Cash FlowCr	-1,153	-523	-709	-667	-330	-570	-972	-885	6,015	-288
Financing Cash Flow Financing Cash FlowCr	654	46	134	-675	-1,116	-686	-817	1,053	-6,358	-304
Net Cash Flow Net Cash FlowCr	-138	61	26	-119	123	58	45	326	82	63
Free Cash Flow Free Cash FlowCr	-558	25	74	722	1,202	835	1,126	-592	81	188
CFO To PAT CFO To PAT%	369.9	190.8	163.6	388.8	882.4	218.6	1,149.2	77.1	126.2	153.6
CFO To EBITDA CFO To EBITDA%	108.6	87.7	69.6	97.3	147.6	88.6	408.4	27.3	55.6	72.8

Financial Year	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	361	537	601	1,223	1,569	1,314	1,834	158	425	656
Investing Cash Flow Investing Cash FlowCr	-1,153	-523	-709	-667	-330	-570	-972	-885	6,015	-288
Financing Cash Flow Financing Cash FlowCr	654	46	134	-675	-1,116	-686	-817	1,053	-6,358	-304
Net Cash Flow Net Cash FlowCr	-138	61	26	-119	123	58	45	326	82	63
Free Cash Flow Free Cash FlowCr	-558	25	74	722	1,202	835	1,126	-592	81	188
CFO To PAT CFO To PAT%	369.9	190.8	163.6	388.8	882.4	218.6	1,149.2	77.1	126.2	153.6
CFO To EBITDA CFO To EBITDA%	108.6	87.7	69.6	97.3	147.6	88.6	408.4	27.3	55.6	72.8

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr			8,447	7,808	4,768	6,858	9,833	12,063	20,438	24,216	34,794	58,245
Price To Earnings Price To Earnings			31.4	23.4	17.1	46.2	18.7	28.4	158.0	4.5	89.7	108.1
Price To Sales Price To Sales			1.3	1.0	0.6	0.8	1.0	4.0	5.5	5.8	7.5	11.9
Price To Book Price To Book			3.4	2.8	1.6	2.3	2.8	3.3	5.4	8.9	9.0	13.8
EV To EBITDA EV To EBITDA			16.9	11.7	7.7	10.7	9.7	38.6	37.6	32.5	39.6	62.3
Profitability Ratios Profitability Ratios
GPM GPM%		56.2	57.1	57.6	57.7	54.7	56.2	40.9	43.0	45.3	46.5	46.5
OPM OPM%	8.5	5.6	9.1	10.8	14.5	12.3	14.5	15.0	15.6	18.5	19.4	19.6
NPM NPM%	0.2	1.6	4.2	4.6	3.6	2.1	5.9	5.3	5.5	8.1	9.2	7.4
ROCE ROCE%		11.1	10.5	10.8	8.6	6.4	10.5	2.9	6.7	11.7	10.8	10.8
ROE ROE%		6.8	11.5	12.9	10.9	5.9	16.8	3.9	4.9	11.0	10.2	10.2
ROA ROA%		1.4	3.8	4.1	2.5	1.5	4.8	1.1	1.1	5.1	5.3	5.3
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr			8,447	7,808	4,768	6,858	9,833	12,063	20,438	24,216	34,794	58,245
Price To Earnings Price To Earnings			31.4	23.4	17.1	46.2	18.7	28.4	158.0	4.5	89.7	108.1
Price To Sales Price To Sales			1.3	1.0	0.6	0.8	1.0	4.0	5.5	5.8	7.5	11.9
Price To Book Price To Book			3.4	2.8	1.6	2.3	2.8	3.3	5.4	8.9	9.0	13.8
EV To EBITDA EV To EBITDA			16.9	11.7	7.7	10.7	9.7	38.6	37.6	32.5	39.6	62.3
Profitability Ratios Profitability Ratios
GPM GPM%		56.2	57.1	57.6	57.7	54.7	56.2	40.9	43.0	45.3	46.5	46.5
OPM OPM%	8.5	5.6	9.1	10.8	14.5	12.3	14.5	15.0	15.6	18.5	19.4	19.6
NPM NPM%	0.2	1.6	4.2	4.6	3.6	2.1	5.9	5.3	5.5	8.1	9.2	7.4
ROCE ROCE%		11.1	10.5	10.8	8.6	6.4	10.5	2.9	6.7	11.7	10.8	10.8
ROE ROE%		6.8	11.5	12.9	10.9	5.9	16.8	3.9	4.9	11.0	10.2	10.2
ROA ROA%		1.4	3.8	4.1	2.5	1.5	4.8	1.1	1.1	5.1	5.3	5.3
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,10,714	82,987	80,785	58,245	55,701	35,414	33,072
Close PriceClose₹	7,700.00	630.90	830.00	668.20	737.80	1,732.90	1,230.00
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.98	88.49	55.37	108.12	53.16	43.13	59.42
Price To SalesPS	4.19	8.03	9.27	11.95	5.86	3.90	7.06
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

	APOLLOHOSP	MANIPALHOS	MAXHEALTH	ASTERDM	FORTIS	NH	MEDANTA
Market CapitalizationMkt CapCr	1,10,714	82,987	80,785	58,245	55,701	35,414	33,072
Close PriceClose₹	7,700.00	630.90	830.00	668.20	737.80	1,732.90	1,230.00
IndustryIndustry	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals	Hospitals
Price To EarningsPE	52.98	88.49	55.37	108.12	53.16	43.13	59.42
Price To SalesPS	4.19	8.03	9.27	11.95	5.86	3.90	7.06
RevenueRevenueCr	26,430	10,336	8,712	4,876	9,506	9,072	4,683
Revenue Growth TTMRev Gr TTM%	17.2%		16.0%	15.7%	17.5%	59.6%	21.3%
PAT Growth TTMPAT Gr TTM%	33.2%		27.0%	3.9%	18.6%	3.9%	3.4%

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26